Experiences with

Daclatasvir

Has anyone took sofusbuvir and daclatasvir and did they get a good response for geno 3?

A successful regimen for HCV patients with all different levels of renal dysfunction has finally been found! Success rates were over 88% and discontinuation rates were also very low, under 12%. http://bit.ly/2jfhMhI

A successful regimen for HCV patients with all different levels of renal dysfunction has finally been found! Success rates were over 88% and discontinuation rates were also very low, under 12%. http://bit.ly/2jfhMhI

http://www.hepmag.com/articles/bms_generic_daclatasvir_2831_28166.shtml?utm_source=phplist36&utm_medium=email&utm_content=HTML&utm_campaign=Success+in+Adding+Sovaldi+to+Hep+C+Re-Treatment

To read more from the press release, click here : http://www.businesswire.com/news/home/20150724005696/en/FDA-Approves-Daklinza-daclatasvir-Treatment-Patients-Chronic#.VbZj6flVikp

Such DDIs would be expected with 70 percent of the HIV regimens if combined with Olysio/Sovaldi, 61 percent with Viekira Pak, 64 percent with Harvoni, and 47 percent with Sovaldi/daclatasvir.

The FDA also last week approved Daklinza (daclatasvir), a treatment developed by Bristol-Myers Squibb to treat genotype-3 infections in combination with Sovaldi. It does not require the co-administration of interferon or ribavirin.

All the participants who took eight weeks of daclatasvir and Sovaldi were treatment naive.. Of those treated for 12 weeks, 101 were treatment naive and 52 were treatment experienced.

All the participants who took eight weeks of daclatasvir and Sovaldi were treatment naive.. Of those treated for 12 weeks, 101 were treatment naive and 52 were treatment experienced.

Included in the list are Gilead Sciences’ Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir), Janssen’s Olysio (simeprevir), Bristol-Myers Squibb’s daclatasvir, and the two components of AbbVie’s Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir), as well as interferon and ribavirin.

Included in the list are Gilead Sciences’ Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir), Janssen’s Olysio (simeprevir), Bristol-Myers Squibb’s daclatasvir, and the two components of AbbVie’s Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir), as well as interferon and ribavirin.

Specifically, the WHO added sofosbuvir (brand name Sovaldi) to the guide, as well as simeprevir (Olysio), daclatasvir, ribavirin and the non-nucleoside polymerase inhibitor dasabuvir.

Bristol-Myers Squibb’s daclatasvir and Gilead Sciences’ Sovaldi (sofosbuvir), with or without ribavirin, offer near-perfect hepatitis C virus (HCV) cure rates among those who have received a liver transplant.

Bristol-Myers Squibb’s daclatasvir and Gilead Sciences’ Sovaldi (sofosbuvir), with or without ribavirin, seem likely to lead to relatively good cure rates among people with genotype 3 of hepatitis C virus.

he combination of sofosbuvir and daclatasvir showed promising results for the treatment of hepatitis C virus (HCV) during a recent clinical trial, which was the first to evaluate this drug combination in a real world setting. - See more at: http://www.specialtypharmacytimes.com/news/Sofosbuvir-Daclatasvir-Combination-Effective-in-Hepatitis-C-Treatment

A recent trial suggests that Bristol-Myers Squibb’s daclatasvir plus Gilead Sciences’ Sovaldi (sofosbuvir), with or without ribavirin, cures high rates of people with genotype 1 of hepatitis C virus (HCV), including those with cirrhosis.

http://fb.me/7iyXKbbYz

http://www.hepmag.com/articles/daclatasvir_sofosbuvir_coinfection_2501_27116.shtml

http://www.poz.com/articles/daclatasvir_sofosbuvir_coinfection_761_27116.shtml

ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B) http://hepatitiscresearchandnewsupdates.blogspot.com/2015/04/ally-1-trial-results-show.html